Director Lewis H. Titterton Jr. filed a Form 4 with the SEC on October 26, 2026, disclosing an open-market purchase of Anixa Biosciences Inc. common stock on October 23, 2026.

Key Highlights

  • Reporting person: Lewis H. Titterton Jr., identified as a Director of Anixa Biosciences Inc. (NASDAQ:ANIX)
  • Transaction: Purchase (transaction code P) of 8,000 shares of common stock on October 23, 2026
  • Price per share: $2.98
  • Post-transaction holdings: 1,054,003 shares of common stock held directly following the reported transaction
  • No derivative securities: Table II contains no reported derivative security transactions

Director Lewis H. Titterton Jr. Adds to Anixa Biosciences Position in October 2026

According to the filing, Lewis H. Titterton Jr., a director of Anixa Biosciences Inc. (NASDAQ:ANIX), acquired 8,000 shares of the company's common stock on October 23, 2026, at a price of $2.98 per share. The transaction is coded "P," indicating an open-market purchase. The filing was signed by Titterton and submitted to the SEC on October 26, 2026.

Following the reported transaction, the filing discloses that Titterton directly and beneficially owns 1,054,003 shares of Anixa Biosciences common stock. The form indicates the securities are held directly. No indirect ownership arrangements are noted in connection with this transaction.

Table II of the filing, covering derivative securities such as options, warrants, and convertible instruments, contains no reported transactions. The filing was made by one reporting person and does not indicate that any transaction was made pursuant to a Rule 10b5-1(c) trading plan, as the corresponding checkbox on the form is not checked.

What Was Disclosed

A director of Anixa Biosciences Inc. disclosed the open-market purchase of 8,000 shares of common stock at $2.98 per share on October 23, 2026, bringing his direct beneficial ownership to 1,054,003 shares.